DXC014 / Hangzhou DAC Biotech - LARVOL DELTA

An Open-Label, Multicenter, First-in-Human, Dose-Escalation and Expansion Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of DXC014 for Injection in Patients with Advanced Solid Tumors. (ChiCTR) - P1 | N=150 | Not yet recruiting | Sponsor: Zhejiang Cancer Hospital; Hangzhou DAC Biotechnology Co.,Ltd.

First-in-human • New P1 trial • Prostate Cancer • Solid Tumor

A Study of DXC014 in Patients With Advanced Solid Tumors. (clinicaltrials.gov) - P1 | N=150 | Not yet recruiting | Sponsor: Hangzhou DAC Biotechnology Co., Ltd.

First-in-human • New P1 trial • Genito-urinary Cancer • Lung Cancer • Melanoma • Oncology • Prostate Cancer • Small Cell Lung Cancer • Solid Tumor

DXC014, a novel bispecific ADC targeting B7-H3 and PSMA, demonstrates favorable antitumor efficacy and safety profiles in preclinical evaluations (AACR 2025) - "These findings underscore the therapeutic potential of DXC014 as a dual-targeting ADC for the treatment of various solid tumors. Its innovative design and excellent preclinical performance position DXC014 as a promising candidate for further clinical development."

Preclinical • Bladder Cancer • Breast Cancer • Genito-urinary Cancer • Head and Neck Cancer • Kidney Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Prostate Cancer • Small Cell Lung Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • CD276 • FOLH1